comprehensive -WSS

comprehensive

author：leisure time 2025-10-01 00:58:54 - browse：41631

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Gilead might be held responsible for not developing a drug

WSS

ReNAgade cuts staff seven months after raising $300 million

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Readout LOUD podcast: How biotech is using artificial intelligence

Gilead might be held responsible for not developing a drug

Flagship Pioneering launches a new biotech in two countries

Gilead might be held responsible for not developing a drug

Wikipedia

comprehensive

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

FDA investigates CAR

Medicare details structure of new drug price negotiation program

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

New air purifier tech could be key to improving indoor air quality

UnitedHealth’s Optum accused of antitrust violations in California

Malaria cases in Florida and Texas: Here’s what you need to know

Why did Pfizer dish out millions for a Super Bowl ad?

The high cost of giving birth even with insurance

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

hotspot

For Medicare Advantage, Democrats want stronger protections around AI

Flagship Pioneering launches a new biotech in two countries

Despite FDA concern, risk that CAR

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

Flagship Pioneering launches a new biotech in two countries

hotspot

hotspot

leisure time

focus